WATCHMAN FLX Pro ヨーロッパレジストリ
WATCHMAN FLX Pro 欧州レジストリ
The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. In a subregistry with approximately 300 patients, it is intended to use the VersaCross Connect™ LAAC Access Solution.
調査の概要
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Catania、イタリア、95123
- Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco
-
Milan、イタリア、20138
- Centro Cardiologico Monzino
-
Verona、イタリア、37126
- Ospedale Sacro Cuore Don Calabria
-
-
-
-
-
Basel、スイス、4031
- University Hospital Basel
-
Bern、スイス、CH-3010
- INSELSPITAL - Universitätsspital Bern
-
-
-
-
-
León、スペイン、24071
- Hospital de Leon
-
Pamplona、スペイン、31008
- Clinica Universidad de Navarra
-
Pontevedra、スペイン、36001
- Complejo Hospitalario Universitario de Pontevedra
-
Pontevedra、スペイン、36001
- Complejo Hospitalario de Pontevedra
-
Salamanca、スペイン、37007
- Hospital Clinico Salamanca
-
-
-
-
-
Aarhus、デンマーク、8200
- Aarhus University Hospital
-
Copenhagen、デンマーク、2100
- Rigshospitalet Copenhagen
-
-
-
-
-
Bad Oeynhausen、ドイツ、32545
- Herz-und Diabeteszentrum Nordrhein-Westfalen
-
Berlin、ドイツ、12203
- Charite, Campus Benjamin Franklin
-
Erfurt、ドイツ、99097
- Kath Krankenhaus St Johann Nepomuk
-
Hamburg、ドイツ、22763
- Asklepios Klinik Altona
-
Hamburg、ドイツ、20099
- Asklepios Klinik Saint Georg
-
Hamburg、ドイツ、22417
- Asklepios Klinik Nord Heidberg
-
Lübeck、ドイツ、23582
- Universitaetsklinikum Schleswig-Holstein
-
-
-
-
-
Poznan、ポーランド、61-848
- Uniwersytecki Szpital Kliniczny w Poznaniu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Hospital
説明
Inclusion Criteria:
- Subject is attempted to be treated with the WATCHMAN FLX™ Pro LAAC device.
- Subject has non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve) and is clinically indicated for a WATCHMAN FLX™ Pro LAAC device, per the Instructions for Use (IFU).
- Subject or legal representative who are willing and capable of providing informed consent.
- Subject is able and willing to return for required follow-up visits and examinations.
- Subject whose age is 18 years or above, or who is of legal age to give informed consent specific to state and national law.
Exclusion Criteria:
- Subject has a documented life expectancy of less than 12 months.
- Subject who is currently enrolled in another investigational study or registry except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments.
- Intracardiac thrombus is present.
- An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.
- The LAA anatomy will not accommodate a Closure Device.
- Subject has a known hypersensitivity or contraindications according to IFU.
- Subject is of childbearing potential and is, or plans to become, pregnant during the time of the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
WATCHMAN FLX Pro
This arm is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. Approximately 300 patients undergo the LAAC procedure in conjunction with the use of the VersaCross Connect™ LAAC Access Solution. |
The WATCHMAN FLX Pro LAAC Technology is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in adult patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy. The VersaCross Connect™ LAAC Access Solution is indicated for the percutaneous introduction of various types of cardiovascular catheters and guidewires to all heart chambers, including the left atrium via transseptal perforation / puncture. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants with a safety event treated with the WATCHMAN FLX Pro
時間枠:Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
Proportion of subjects with one or more of the following events between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention such as pseudoaneurysm repair, AV fistula repair, or other major endovascular repair. Percutaneous catheter drainage of pericardial effusions, snaring of an embolized device, thrombin injection to treat femoral pseudoaneurysm and minor nonsurgical treatments of access site complications are excluded from this endpoint. |
Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
|
Number of participants with a safety event treated with the VersaCross Connect™ LAAC Access Solution
時間枠:Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
Proportion of subjects with one or more of the following events between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later: For all enrolled subjects, who had an attempt to insert the VersaCross Connect™ LAAC Access Solution device, the composite rate of all-cause death, all stroke, systemic embolism, pericardial effusion resulting in interventions*, and ISTH major bleeding. *Pericardial effusion/tamponade requiring pericardiocentesis or surgery to treat |
Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
|
Number of participants with a successful VersaCross Connect™ LAAC Access Solution treatment
時間枠:Completion of transseptal puncture
|
VersaCross Connect™ LAAC Access Solution acute procedural success: Acute Procedural Success is defined as transseptal puncture success (VersaCross RF-wire crossing into left atrium). |
Completion of transseptal puncture
|
協力者と研究者
捜査官
- 主任研究者:Arian Sultan, Prof. MD、Asklepios Klinik Saint Georg
- 主任研究者:Marek Grygier, Prof. MD, PHD、Uniwersytecki Szpital Kliniczny w Poznaniu
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。